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Abstract
Purpose Along with a number of other malignancies, the term “oligometastatic” prostate cancer has recently emerged. It 
represents an attempt to define a subtype of cancer with a limited metastatic load that might perform more favorably than 
a distinctly disseminated disease, or even one that may be managed in a potentially curative way. Since there is currently 
a knowledge gap of what imaging modalities should be utilized to classify patients as having this type of tumor, we aimed 
to shed light on the role of conventional and marker-based imaging in the setting of synchronous oligometastatic prostate 
cancer as well as summarize the available evidence for its clinical application.
Methods A literature search on December 15th 2017 was conducted using the Pubmed database.
Results Functional imaging techniques like 68Ga PSMA. 68Ga PSMA PET-CT has currently been shown the best detection 
rates for the assessment of nodal, bone and visceral metastases, especially for smaller lesions at low PSA levels.
Conclusions Functional imaging helps detect low-burden disease metastatic patients. However, these imaging modalities are 
not available in every center and thus clinicians may be prone to prescribe systemic treatment rather than referring patients 
for cytoreductive treatments. We hope that the ongoing prospective trials will help guide clinicians in making a more per-
sonalized management of synchronous metastatic patients.
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Introduction
A total of 416,700 new cases of prostate cancer (PCa) were 
estimated to occur in Europe in 2012, while 92,200 males 
would succumb, making PCa besides non-melanoma skin 
cancers the most frequently diagnosed malignancy and at 
the same time the third leading cause of cancer death in 
men [1]. In non-metastatic disease, curative risk adapted 
approaches incorporating life expectancy, comorbidities and 
treatment preference, and at the same time accounting for the 
presumed clinical stage of the tumor, are offered for patients 
to choose between active surveillance, focal therapy, radical 
prostatectomy (RP) or radiation therapy (RT) accompanied 
by excellent survival probabilities [2].
Fortunately, only less than 1 out of 20 males with PCa 
is nowadays diagnosed with a de novo systemically dis-
seminated cancer due to a wide adoption of PSA screen-
ing [3]. Once metastasized, primarily or progressing after 
local treatment, disease is, however, believed incurable and 
only manageable with palliative intent. Since Huggins and 
Hodges determined the hormonal dependence of PCa in the 
1940s [4], androgen deprivation therapy (ADT) has been the 
frontline treatment for metastatic disease. However, disease 
progression to castration-resistant PCa (CRPCa) inevitably 
occurs after 2–3 years of ADT [5].
In general, disease classification as “metastatic” as 
opposed to “clinically localized” relies on the presence of 
metastatic lesions on conventional imaging, i.e., lymphatic 
or visceral metastases on computed tomography (CT) or 
magnetic resonance imaging (MRI) as well as osseous 
metastases on bone scan in accordance with recommenda-
tions of the European Association of Urology on imaging for 
disease staging [6]. In the past, men with metastatic disease 
were usually deprived of a local treatment (and subjected to 
ADT) under the assumption that this therapy may not exert 
any positive influence on the following course of the disease 
and may expose patients to unnecessary treatment-related 
morbidity. Consequently, it was carried out solely in highly 
selected cases experiencing local complications. Common 
practice was, e.g., the abandonment of RP if pelvic lymph 
node dissection demonstrated lymphatic metastasis on fro-
zen section analysis. However, evidence emerged later that 
patients with positive nodes and complete RP have a survival 
advantage over their counterparts with abandoned RP [7, 8]. 
Thus, a number of patients with limited extent of dissemi-
nated disease might still benefit from local treatment (RP or 
RT), not only in terms of its alleviating local symptoms as a 
palliative care but also by experiencing a survival advantage 
(if not a cure) via a multimodal approach [9–11].
Ongoing challenge for a treating physician hence con-
sists of identifying patients whose disease has progressed 
systemically, but in whom a local therapy combined with 
metastasis-directed and/or adjuvant systemic therapy might 
be possible. In this context, the term “oligometastatic dis-
ease” represents an attempt to define such a population of 
PCa patients. In view of a virtual revolution achieved in the 
last years in the area of molecular imaging modalities in 
PCa allowing for an improved sensitivity and specificity of 
metastasis detection in small-volume disease, it is apparent 
that the numbers of patients detected with a low-burden dis-
seminated cancer as compared to localized disease will rise 
in the future, since occult lesions missed with conventional 
imaging may be better visualized with these novel methods.
Since there is neither unanimous consent on how to 
exactly classify this disease nor what imaging should be 
utilized for its definition, we strived to review the available 
evidence on conventional and molecular imaging modalities 
and their current and possible future clinical implication in 
the setting of the synchronous oligometastatic PCa (OPCa).
Oligometastatic disease
Oligometastasis was first described by Hellmann and Weich-
selbaum in 1995, as they postulated that tumor progression 
occurs in a multistep fashion during its clinical evolution and 
the number and sites of metastatic lesions may reflect the 
state of tumor development [12]. According to this theory, 
there are intermediate cancer stages between purely local-
ized and widely metastatic. Tumors in their early state of 
progression possess only a low dissemination capacity and 
hence lead to a few lesions limited to organs with the highest 
host receptivity offering optimal conditions for growth, pro-
liferation and angiogenesis and where these cells are with a 
fragile invasive behavior may survive. Following this, malig-
nant seeding capacity intensifies and promotes a multifocal 
dissemination. The authors also proposed that some patients 
bearing oligometastatic disease might be treated with cura-
tive intent.
In 2004, Singh et al. [13] were the first to use the term 
“oligometastatic disease” in the setting of PCa. They 
reported that PCa patients, who were initially treated with 
RT for localized/locally advanced disease and later devel-
oped OPCa (defined as ≤ 5 lesions; metachronous oligo-
metastasis), had a superior survival over their counterparts 
with a more extended dissemination. They proposed to treat 
patients with OPCa aggressively to counteract further sys-
temic seeding from metastatic lesions and improve long-
term survival.
Traditionally, OPCa is referred to as a low-volume tumor 
burden up to 3–5 metastases in bone and/or lymph nodes 
on conventional imaging [3, 14]. Of note, novel imaging 
modalities such as 11C-Choline, 11C-Acetate, 18F-FDG 
or 18F-Choline PET-CT have also been used to classify 
patients as having OPCa [15–18]. Importantly, it is still 
World Journal of Urology 
1 3
unclear whether OPCa is simply a transitory phenomenon 
from clinically localized to polymetastatic cancer and shares 
similar molecular features with a high-burden disease [14]. 
Alternatively, the underlying biology at the molecular level 
in OPCa cells might be different to polymetastatic disease. 
Preclinical data suggest that oligometastatic progression of 
tumors is substantially driven by epigenetic alterations and, 
in particular, miRNAs, whereas polymetastatic dissemina-
tion is characterized by overexpression of genes associated 
with cell division and cell cycle progression [19–21]. This 
scenario might also hold true for PCa. Further comprehen-
sive research in PCa is urgently needed to elucidate if there 
are really different molecular mechanisms between the true 
oligometastatic and pseudo-oligometastatic disease, which 
has already disseminated to a considerable extent with occult 
lesions, to facilitate selection of patients for local and/or 
metastases-targeted and/or adjuvant systemic therapy vs. 
palliative systemic treatment [14]. In addition, molecular 
classifiers are welcomed to pigeonhole OPCa patients with 
a predominantly androgen receptor-driven disease and for 
whom ADT or abiraterone would be an effective treatment 
as an adjuvant approach as opposed to those who might pro-
gress rapidly to CRPC. In particular, there might be some 
histological subtypes of PCa, such as ductal or neuroendo-
crine/small cell variants, which might benefit most from 
chemotherapy even in the oligometastatic state [22].
CT and MRI
Both CT and MRI are the mainstay of whole-body mor-
phological imaging; functional techniques in MRI provide 
additive data [23]. The imaging depicted metastatic state 
is key to patient management for biomarker development 
and for therapeutic clinical trials [24]. The literature shows 
a broad range in the diagnostic performance of both unen-
hanced CT and MRI in the detection of lymph node metas-
tases. CT and MRI demonstrate an equally poor perfor-
mance in the detection of lymph node metastases from 
PCa. Reliance on either CT or MRI will misrepresent the 
patient’s true status regarding nodal metastases, and thus 
misdirect the therapeutic strategies offered to the patient 
[25].
Whole-body MRI (WB-MRI) with conventional T1, T2 
and inversion recovery sequences provides high tissue con-
trast for bone metastasis detection [26, 27]. The addition of 
diffusion-weighted imaging (DWI) to WB-MRI enables the 
study of extra-skeletal involvement, including lymph nodes 
and other soft-tissue metastases, without requiring intrave-
nous contrast agents [28, 29]. The reported sensitivity and 
specificity for WB-MRI ranges from 98 to 100% and 98 to 
100%, respectively. Inter-observer agreement for reading of 
WB-MRI images that include DW is very good (K = 0.87 
[0.66; 1.00]) [27]. Furthermore, DWI in WB-MRI will allow 
quantification of tumor load [30]. The METastasis Report-
ing and Data System for Prostate Cancer (MET-RADS-P) 
imaging recommendations are designed to promote stand-
ardization and diminish variations in the acquisition, inter-
pretation, and reporting of WB-MRI in advanced prostate 
cancer. The MET-RADS-P system provides comprehensive 
characterization of advanced PCa state, not only at the start 
of treatments but also over time as the disease evolves [30] 
(Fig. 1).
Bone scan
For the staging of bone metastases, 99mTechnetium-meth-
ylene diphosphonate bone scintigraphy (‘bone scan’) is the 
traditional established imaging modality. In patients with 
primary PCa, the current guidelines recommend a bone scan 
if there are symptoms suggestive of bone metastasis, or in 
asymptomatic patients when the PSA level is > 10 ng/ml, 
Gleason score ≥ 8 or clinical stage ≥ T3 (i.e., intermediate- 
and high-risk tumors) [6]. Bone scan has the disadvantage 
that it only assesses the skeleton and that it is hampered by 
a large number of inconclusive results warranting additional 
imaging with radiography, CT or MRI in about 16% of the 
cases [31, 32]. A bone scan can readily detect polymetastatic 
disease in symptomatic patients or in patients with PSA 
levels of ≥ 50 ng/ml with reported sensitivities of 78–95%, 
specificities of 72–100%, positive predictive value of 96% 
and negative predictive value of 60% [32, 33]. In asympto-
matic patients the diagnostic yield is highly dependent on 
the PSA level, with positivity rates of only 2.3% for PSA 
levels of 0–9.9 ng/ml, 5.3% for PSA levels of 10–19.9 ng/ml 
and 16.2% for PSA levels of 20–49.9 ng/ml [34]. In recent 
years, with the advent of whole-body MRI and PET-CT as 
new comparators, the true overall sensitivity of bone scan-
ning has appeared to be only around 65%, suggesting that a 
significant amount of metastatic lesions may go undetected 
[27, 35]. Bone scan thus seems to systematically underesti-
mate the burden of bone metastases in the primary staging 
of PCa and consequently performs insufficiently to reliably 
classify patients as oligometastatic [23, 35].
PET‑CT and PET‑MRI
Recent developments in molecular imaging, in particular 
positron emission tomography (PET) using targeted PCa 
tracers, have demonstrated great promise in more accurate 
assessment of patients with oligometastatic disease [36]. The 
combination of metabolic PET imaging with morphological 
imaging in a hybrid PET-CT or PET-MRI exam has over-
come the limitations of conventional imaging, particularly 
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in the early detection of a limited number of metastases and 
in the setting of low PSA levels [35, 37]. Advantages of 
PET-MRI over PET-CT include less exposure to radiation 
and better correlation of a hot spot on PET with the intrapro-
static lesion or changes in the bone marrow, but there is 
still poor clinical evidence of PET-MRI at this time [38]. 
In PCa, PET-CT has been investigated mainly for restaging 
of patients with biochemical recurrence after treatment but 
there is a growing body of evidence supporting its use in 
primary staging [35, 39, 40].
18F Fluoro-deoxy-glucose (FDG)-PET is the mainstay of 
molecular imaging and has demonstrated clinical usefulness 
in many tumors but has proven to be of limited value in PCa 
[31, 41]. Radiopharmaceutical agents showing a tropism for 
PCa cells such as 11C acetate, 11C choline and 18F choline 
have been introduced around the turn of the century, and, 
in the last 10 years predominantly choline-based tracers 
have been used in clinical practice [41–44]. While the early 
results were promising, the utility of choline PET-CT has 
been limited in the oligometastatic setting due to reduced 
sensitivity in patients with low PSA and in the early stages 
of metastatic spread [37]. Moreover, choline is not neces-
sarily cancer-specific and it shows also uptake in areas of 
benign inflammation causing false-positive results in, for 
example, reactive lymph nodes [35]. The most promising 
data to date have been generated with radiotracers target-
ing the prostate-specific membrane antigen (PSMA) which 
is overexpressed in PCa cells [35, 45]. Initially reported 
in 2012, 68Ga PSMA HBED-CC PET-CT has shown to 
be superior to the older tracers predominantly owing to 
increased avidity of uptake and higher target-to-background 
ratio, resulting in an improved detection rate [45, 46]. Other 
emerging innovative PET radiotracers for PCa have been 
proposed such as 18F-Fluciclovine (FACBC), 18F-Bombesin, 
18F-fluoro-5α-dihydrotestosterone (FDHT) and urokinase-
type plasminogen activator receptor (uPAR), but these are 
almost exclusively being investigated in the setting of recur-
rent PCa or for visualization of the primary intraprostatic 
lesion but not for distant staging in primary PCa [41].
Regarding nodal staging in the primary setting, an 
extended pelvic lymphadenectomy still represents the gold 
standard and accurate imaging modalities are currently lack-
ing. Metastatic lymph nodal spread is present in approxi-
mately 20–35% of the intermediate- and high-risk patients 
but they are the most common site of occult disease in de 
novo settings [46–48]. PET-CT has been shown to be supe-
rior as compared to conventional morphological CT or MRI 
in preoperative lymph node assessment [25, 49]. PET-CT 
using 11C choline or 18F choline tracers have shown a rela-
tively good specificity of 89.5–99.7% and positive predictive 
Fig. 1  73-year-old man with a Gleason 4 + 3 PCa pT3 with PSA of 
18.2 ng/ml. A whole-body MR examination was performed. Coronal 
whole body T1-weighted image (a) shows a left iliac bone metastasis 
(b; magnification; arrows). The bone metastasis (arrows) are evident 
on whole-body DWI images (c, d). e In the right lung, para-hilar, a 
15 mm metastasis was observed (circle)
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value of 63.6–98.0% but only moderate sensitivity (ranging 
from 10 to 67%) for detecting involved lymph nodes [39, 
41, 44, 49–54]. The sensitivity is higher in high-risk PCa 
patients (83.3%) than in the intermediate-risk group (33.3%) 
[49]. Choline PET-CT could thus provide helpful additional 
information in patients with suspected oligometastatic dis-
ease but since sufficient detection rates are not reached as 
compared to surgical lymph node dissection, its routine 
clinical use is not recommended at present to detect occult 
lymph node metastases in all patients with high-risk PCa in 
whom CT scan findings are normal [6, 50, 52, 53, 55].
In addition, for the staging of bone metastasis, PET-CT 
appears to perform better than bone scan because tracer 
uptake may be detected in early bone marrow infiltration 
before osteoblastic reaction occurs (Fig. 2). A meta-analysis 
evaluating choline PET-CT in the diagnosis of bone involve-
ment in intermediate or high-risk primary PCa patients 
showed a pooled sensitivity of 49% and a pooled specificity 
of 95% [31, 39, 51]. The poor sensitivity is largely due to 
non-recognition of early bone metastases, although choline 
or fluoride PET-CT detect bone metastases in up to 56% 
of patients with a negative or inconclusive bone scan [55, 
56]. Nevertheless, because of the similar sensitivity, choline 
PET-CT should not replace bone scan to date.
68Ga PSMA PET-CT has currently been shown the best 
detection rates for the assessment of nodal, bone and vis-
ceral metastases, especially for smaller lesions at low PSA 
levels [37]. Gupta et al. [46] reported that in patients with 
newly diagnosed PC and high clinical suspicion of metas-
tases (Gleason score 9–10 and/or serum PSA > 20 ng/ml) 
but nil or ≤ 3 metastases on conventional imaging (CT 
and bone scan) at least 1 lesion was detected in 100% of 
PSMA PET-CT. 68Ga PSMA PET-CT in primary staging 
found bone metastasis in 13% of asymptomatic patients 
with PSA < 10 ng/ml, although these patients would nor-
mally not have a bone scan in routine clinical practice [46]. 
In the systematic review of Perera [40] the pooled percent-
age of positive 68Ga PSMA PET-CT was 40% (95% confi-
dence interval 19–64%) in the primary staging. Of all stud-
ies, 24% showed only oligometastases (≤ 3), and 62.5% of 
these concerned a solitary lesion. Moreover, a high rate of 
incidental extra-pelvic disease (41%) was observed [46]. 
Recently, another systematic review on the currently avail-
able data on 68Ga PSMA PET-CT in the primary staging of 
high-risk PCa was published [57]. A high variation in sen-
sitivity (range 33–99%) was seen across the studies but with 
consistently high specificity (> 90%). Twelve studies were 
included but only five could be classified as high quality 
because they correlated imaging findings with histopathol-
ogy. The lack of histologic correlation with positive (and 
indeed negative) PSMA PET-CT results makes it unclear 
as to the true accuracy of this novel imaging modality. 
Nonetheless, preoperative staging with 68Ga PSMA PET-
CT appears to allow for more complete and accurate pri-
mary staging of PCa patients compared to standard routine 
imaging and may demonstrate a large number of otherwise 
unknown metastatic lesions, but its clinical role is yet to be 
definitively determined [40]. PET-CT has been reported to 
alter treatment plans in 29–76% of patients as compared to 
staging with conventional imaging [37, 39, 49, 56]. A large 
proportion of the additionally detected metastatic lesions 
are oligometastatic and in the future, with increasing use of 
68Ga PSMA PET-CT, we may expect to identify a substan-
tial higher number of patients with oligometastasis at initial 
presentation (Fig. 3). The clinical impact and cost effective-
ness of potentially replacing current standard imaging for 
68Ga PSMA PET-CT in the primary setting needs, therefore, 
to be confirmed by prospective studies with oncological out-
comes, but despite this current lack of evidence, 68Ga PSMA 
PETC-CT seems to be increasingly performed in clinical 
practice in countries where it is available [37].
Clinical implications
The rationale for using local treatment, as the first step in the 
management of de novo metastatic PCa, such as radical pros-
tatectomy and radiotherapy is based on: a potential benefit 
in terms of improved local control, removal of the primary 
source for metastasis and (possibly) improved response to 
systemic treatments [58]. To this day, only retrospective 
population-based data, from different cancer registries such 
as Surveillance, Epidemiology, and End Results (SEER), 
National Cancer Database and several institutional data, sup-
port these assumptions. Despite the lack of level 1 evidence, 
approximately 75% of the panelists from the Advanced Pros-
tate Cancer Consensus Conference (APCCC) 2017 agreed 
that there is a need for some form of local treatment in men 
with oligometastatic disease [59].
Although the results confirm the feasibility of cytoreduc-
tive RP, it is still unclear who would benefit from resec-
tion of the primary tumor. The ideal candidate might be a 
fit patient with ≤ T3 stage, Gleason score ≤ 7, low-volume 
metastatic disease, no visceral metastases and a low PSA 
nadir after 6 months of systemic therapy. Furthermore, 
imaging might be of use for selecting these candidates. The 
ongoing prospective randomized trials such as TRoMBone 
(ISRCTN15704862) and g-RAMPP (NCT02454543) will 
provide level 1 evidence regarding the role of surgery in 
patients with synchronous oligometastatic disease [60, 61].
A clinical decision based on the available data should 
be taken with caution due to significant limitations of these 
studies and unknown confounders: limited to no informa-
tion regarding the associated comorbidities, different defi-
nitions of the oligometastatic state, different endpoints and 
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unavailable data regarding the imaging techniques used for 
detection of distant lesions. Furthermore, data regarding 
treatments such as ADT, chemotherapy or dosage of radio-
therapy are largely unavailable.
Role of metastasis‑directed therapies
Technical improvements in surgery and radiotherapy have 
introduced the option of metastasis-directed ablative thera-
pies as an adjunct or alternative to standard-of-care systemic 
therapies [23]. More sensitive imaging will increase the like-
lihood of the detection of metastatic disease. However, none 
of the historic trials have incorporated any of these novel 
imaging modalities.
In a study by Sterzing et al., [62] 9 out of the 15 patients 
identified for primary staging by 68Ga-PSMA PET, were 
found to have metastatic lesions. Based on the results, 
approximately 51% of patients received a different thera-
peutic approach compared to the initial plan based upon 
conventional staging methods. Eight out of 15 patients were 
changed from M0 to M1a disease, which resulted in enlarged 
lymphatic field irradiation. These patients were all included 
in the historical trials as conventional imaging M0-status, 
whereas that with the current novel imaging techniques that 
the same number of patients was N1/M1 on novel imag-
ing. Nevertheless, the disease control rates in these trials are 
already high [63, 64]. This begs the question whether change 
in management should be based on this novel imaging out-
side a trial as we have little evidence that metastasis-directed 
therapy influences a major endpoint in this setting.
Future perspectives
In absence of more robust evidence from clinical trials, it 
is critical to be aware of how increasing availability and 
practical utilization of marker-based imaging in supposed 
non-metastatic disease, particularly PSMA PET-CT, with 
all its diagnostic accuracy may change treatment paradigms 
and de facto make decision-making process notably deli-
cate nowadays, not least due to patients` wish. Since patients 
diagnosed with PCa increasingly obtain information on their 
disease on the Web, it is encouraging that quality, accessibil-
ity, and usability of the respective websites has been rated 
high in a contemporary analysis [65]. However, promising 
data on PSMA PET-CT exhibited there, are not ultimately 
accompanied by correct indications boosting demands for 
this imaging modality by laypersons even in disease set-
tings without guideline recommendation for its use. The 
practice of performing PSMA PET-CT as primary staging 
in patients with high-risk localized or locally advanced dis-
ease has already become a reality in some scenarios. These 
patients would be treated with radical prostatectomy (± adju-
vant radiotherapy) or primary radiotherapy + ADT based 
on the findings on conventional imaging (bone scan and 
CT) according to the EAU guidelines [2] but using PSMA 
PET-CT we would diagnose occult OPCa in some of them. 
Emerging dilemma is how this finding would influence our 
treatment strategy and how the cut-off for performing or 
not local treatment should be defined? Would we deprive 
patients of efficient local therapy eventually combined with 
currently still low-evidenced metastasis-directed therapy 
replacing it by escalated systemic treatment? Of note, 
long-term survival analysis of the CHAARTED Trial dem-
onstrated a trend for patients with low-volume disease to 
perform even worse on chemohormonal treatment than on 
ADT (4% more deaths, p = 0.86) [66]. On the other hand, 
using PSMA PET-CT in some OPCa patients (as defined by 
conventional imaging) would screen out those with false-
positive results, e.g., benign findings as bone hemangiomas, 
potentially shifting them to the cohort with clinically local-
ized disease and enabling primary curative therapy. Until 
these issues are not sufficiently clarified by the results of 
solid clinical trials, staging of primary Pca in routine clinical 
practice should still be performed with conventional imaging 
(bone scan and CT), although we are aware of the limita-
tions. In institutions where PSMA PET-CT is available, it 
could be used additionally in cases of suspected OPCa to 
confirm the limited number of metastatic lesions but then we 
are left to rely on empirical decisions and treatment strategy 
remains challenging.
Conclusion
Ultimately, the decision regarding when and how to treat 
men with OPCa requires an assessment of the risks of 
burden of therapy versus risks of death derived from fac-
tors such as disease progression, associated comorbidities, 
metastatic load and access to medical facilities. With the 
recent data from the CHAARTED [67] and LATITUDE 
trials [68], an interesting question arises: is conventional 
imaging enough to accurately stage a patient in modern era? 
Fig. 2  53-year-old man with a Gleason 4 + 4 PCa pT3 with PSA of 
12.5 ng/ml. Primary staging with bone scan showed no lesions sus-
picious for bone metastases (a), but because he complained of right 
shoulder pain a 18F choline PET-CT was performed. This demon-
strated focal tracer uptake in the spina scapulae (b, white arrow), 
indicating a bone metastase. On the corresponding CT image the 
scapula was unremarkable. Choline PET-CT may demonstrate bone 
metastases that are occult on bone scan and CT because it can detect 
changes in the bone marrow before osteoblastic reaction occurs. Nev-
ertheless, bone scan currently remains the standard imaging modality 
in the primary staging of PCa
◂
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Functional imaging helps detect low-burden disease meta-
static patients who are not likely to benefit from chemo-
therapy. However, these imaging modalities are not available 
in every center and thus clinicians may be prone to prescribe 
systemic treatment rather than referring patients for cytore-
ductive treatments. We hope that the ongoing prospective 
trials will help guide clinicians into making a more personal-
ized management of synchronous metastatic patients.
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